亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

ABC50: Technology Enhancing Protein and Mono-Clonal Antibody Production

技術應用: Enhancementof therapeutic protein production in mammalian cellsReagentmanufacturing for in vitro diagnostics and research

詳細技術說明: Technology that enhances levels of protein expression in mammalian cells

*Abstract: The combined market for therapeutic, research and diagnosticproteins is currently more than $100 billionworldwide and rapidly growing. Approximately half of the 140 recombinantproteins currently on the market are produced in mammalian cells. Given therequirement for large amounts of protein and the high costs of upstreammanufacturing processes, the pharmaceutical industry needs technologies thatenhance protein production in mammalian cells.

Dr. Stuart Berger hasdeveloped a proprietary method to boost protein expression and production ofmonoclonal antibodies by as much as 3-fold. The method involves overexpressionof ABC50, a protein involved in the initiation of protein translation. Potential applications of this technologyinclude its use in the generation of cell lines with improved proteinproduction and survival properties for the industrial production ofbiopharmaceuticals.

In addition totherapeutic proteins, Dr. Berger’s technology can be used in other sectors suchas reagent manufacturing for clinical diagnostics (in vitro diagnostics) andlaboratory research.
Antibody productionis boosted in ABC50-overexpressing cells. ABC50-overexpressingCHO cells (ABC50) or vector control CHO cells (vector) were cultured inserum-free media for 3 days. Culture supernatants were removed and tested for antibodycontent by ELISA.

欲了解更多信息，請點擊這裡